Literature DB >> 21985244

Stimulatory effect of α-synuclein on the tau-phosphorylation by GSK-3β.

Fumitaka Kawakami1, Minori Suzuki, Naoki Shimada, Go Kagiya, Etsuro Ohta, Kei Tamura, Hiroko Maruyama, Takafumi Ichikawa.   

Abstract

Hyperphosphorylation of tau protein (tau) causes neurodegenerative diseases such as Alzheimer's disease (AD). Recent studies of the physiological correlation between tau and α-synuclein (α-SN) have demonstrated that: (a) phosphorylated tau is also present in Lewy bodies, which are cytoplasmic inclusions formed by abnormal aggregation of α-SN; and (b) the neurotoxin 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP) increases the phosphorylation of tau as well as the protein level of α-SN in cultured neuronal cells, and also in mice. However, the molecular mechanism responsible for the α-SN-mediated hyperphosphorylation of tau remains to be elucidated. In this in vitro study, we found that: (a) α-SN directly stimulates the phosphorylation of tau by glycogen synthase kinase-3β (GSK-3β), (b) α-SN forms a heterotrimeric complex with tau and GSK-3β, and (c) the nonamyloid beta component (NAC) domain and an acidic region of α-SN are responsible for the stimulation of GSK-3β-mediated tau phosphorylation. Thus, it is concluded that α-SN functions as a connecting mediator for tau and GSK-3β, resulting in GSK-3β-mediated tau phosphorylation. Because the expression of α-SN is promoted by oxidative stress, the accumulation of α-SN induced by such stress may directly induce the hyperphosphorylation of tau by GSK-3β. Furthermore, we found that heat shock protein 70 (Hsp70) suppresses the α-SN-induced phosphorylation of tau by GSK-3β through its direct binding to α-SN, suggesting that Hsp70 acts as a physiological suppressor of α-SN-mediated tau hyperphosphorylation. These results suggest that the cellular level of Hsp70 may be a novel therapeutic target to counteract α-SN-mediated tau phosphorylation in the initial stage of neurodegenerative disease.
© 2011 The Authors Journal compilation © 2011 FEBS.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21985244     DOI: 10.1111/j.1742-4658.2011.08389.x

Source DB:  PubMed          Journal:  FEBS J        ISSN: 1742-464X            Impact factor:   5.542


  29 in total

1.  GSK-3β dysregulation contributes to parkinson's-like pathophysiology with associated region-specific phosphorylation and accumulation of tau and α-synuclein.

Authors:  J J Credle; J L George; J Wills; V Duka; K Shah; Y-C Lee; O Rodriguez; T Simkins; M Winter; D Moechars; T Steckler; J Goudreau; D I Finkelstein; A Sidhu
Journal:  Cell Death Differ       Date:  2014-11-14       Impact factor: 15.828

2.  Role of GSK3β/α-synuclein axis in methamphetamine-induced neurotoxicity in PC12 cells.

Authors:  Lizeng Li; Si Chen; Yue Wang; Xia Yue; Jingtao Xu; Weibing Xie; Pingming Qiu; Chao Liu; AiFeng Wang; Huijun Wang
Journal:  Toxicol Res (Camb)       Date:  2017-12-22       Impact factor: 3.524

Review 3.  Tau acts as a mediator for Alzheimer's disease-related synaptic deficits.

Authors:  Dezhi Liao; Eric C Miller; Peter J Teravskis
Journal:  Eur J Neurosci       Date:  2014-04       Impact factor: 3.386

Review 4.  Roles of tau protein in health and disease.

Authors:  Tong Guo; Wendy Noble; Diane P Hanger
Journal:  Acta Neuropathol       Date:  2017-04-06       Impact factor: 17.088

5.  A53T Mutant Alpha-Synuclein Induces Tau-Dependent Postsynaptic Impairment Independently of Neurodegenerative Changes.

Authors:  Peter J Teravskis; Ana Covelo; Eric C Miller; Balvindar Singh; Héctor A Martell-Martínez; Michael A Benneyworth; Christopher Gallardo; Breeta R Oxnard; Alfonso Araque; Michael K Lee; Dezhi Liao
Journal:  J Neurosci       Date:  2018-09-24       Impact factor: 6.167

Review 6.  The Role of α-Synuclein and LRRK2 in Tau Phosphorylation.

Authors:  Fumitaka Kawakami; Takafumi Ichikawa
Journal:  Parkinsons Dis       Date:  2015-04-21

Review 7.  Innovative treatment targeting gangliosides aimed at blocking the formation of neurotoxic α-synuclein oligomers in Parkinson's disease.

Authors:  Nouara Yahi; Coralie Di Scala; Henri Chahinian; Jacques Fantini
Journal:  Glycoconj J       Date:  2021-07-30       Impact factor: 2.916

8.  Low CSF levels of both α-synuclein and the α-synuclein cleaving enzyme neurosin in patients with synucleinopathy.

Authors:  Malin Wennström; Yulia Surova; Sara Hall; Christer Nilsson; Lennart Minthon; Fredrik Boström; Oskar Hansson; Henrietta M Nielsen
Journal:  PLoS One       Date:  2013-01-08       Impact factor: 3.240

9.  A powerful yeast model to investigate the synergistic interaction of α-synuclein and tau in neurodegeneration.

Authors:  Gianmario Ciaccioli; Ana Martins; Cátia Rodrigues; Helena Vieira; Patrícia Calado
Journal:  PLoS One       Date:  2013-02-05       Impact factor: 3.240

10.  Tau knockout exacerbates degeneration of parvalbumin-positive neurons in substantia nigra pars reticulata in Parkinson's disease-related α-synuclein A53T mice.

Authors:  Luyan Jiao; Meige Zheng; Jinhai Duan; Ting Wu; Zhao Li; Lin Liu; Xianhong Xiang; Xiaolu Tang; Jinyang He; Xingjian Li; Guofeng Zhang; Jinhui Ding; Huaibin Cai; Xian Lin
Journal:  FASEB J       Date:  2020-07-30       Impact factor: 5.834

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.